HAROLD DVORAK

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Discovery of vascular permeability factor (VPF)
    Harold F Dvorak
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, 99 Brookline Avenue, Boston, MA 02215, USA
    Exp Cell Res 312:522-6. 2006
  2. pmc Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets
    Janice A Nagy
    Departments of Pathology, The Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Ave, RN227C, Boston, MA 02215, USA
    Clin Exp Metastasis 29:657-62. 2012
  3. pmc Vascular permeability, vascular hyperpermeability and angiogenesis
    Janice A Nagy
    Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Angiogenesis 11:109-19. 2008
  4. pmc Tumor microenvironment and progression
    Harold F Dvorak
    Department of Pathology, Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    J Surg Oncol 103:468-74. 2011
  5. pmc Vascular permeability to plasma, plasma proteins, and cells: an update
    Harold F Dvorak
    Center for Vascular Biology Research and the Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Curr Opin Hematol 17:225-9. 2010
  6. pmc Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma
    Harold F Dvorak
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Am J Pathol 162:1747-57. 2003
  7. ncbi request reprint Angiogenesis: update 2005
    H F Dvorak
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    J Thromb Haemost 3:1835-42. 2005
  8. ncbi request reprint Down syndrome candidate region 1 isoform 1 mediates angiogenesis through the calcineurin-NFAT pathway
    Liuliang Qin
    Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, 99 Brookline Avenue RN 270A, Boston, MA 02215, USA
    Mol Cancer Res 4:811-20. 2006
  9. ncbi request reprint Stable expression of angiopoietin-1 and other markers by cultured pericytes: phenotypic similarities to a subpopulation of cells in maturing vessels during later stages of angiogenesis in vivo
    Christian Sundberg
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
    Lab Invest 82:387-401. 2002
  10. pmc Vascular permeability and pathological angiogenesis in caveolin-1-null mice
    Sung Hee Chang
    Center for Vascular Biology Research and the Departments of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Am J Pathol 175:1768-76. 2009

Collaborators

Detail Information

Publications27

  1. ncbi request reprint Discovery of vascular permeability factor (VPF)
    Harold F Dvorak
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, 99 Brookline Avenue, Boston, MA 02215, USA
    Exp Cell Res 312:522-6. 2006
  2. pmc Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets
    Janice A Nagy
    Departments of Pathology, The Center for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Ave, RN227C, Boston, MA 02215, USA
    Clin Exp Metastasis 29:657-62. 2012
    ..The future of anti-vascular cancer therapy may depend on finding new targets on "late" vessels, apart from those associated with the VEGF/VEGFR axis...
  3. pmc Vascular permeability, vascular hyperpermeability and angiogenesis
    Janice A Nagy
    Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Angiogenesis 11:109-19. 2008
    ..Further work will be required to elucidate the signaling pathways by which each of these molecules, and others likely to be discovered, mediate the different types of vascular permeability...
  4. pmc Tumor microenvironment and progression
    Harold F Dvorak
    Department of Pathology, Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    J Surg Oncol 103:468-74. 2011
    ..Also, breast cancers arise as the result of epigenetic as well as genetic changes. Tumor blood vessel pericytes result, in part, from bone marrow precursor cells, and VEGF is a negative regulator of glioblastoma tumor cell invasion...
  5. pmc Vascular permeability to plasma, plasma proteins, and cells: an update
    Harold F Dvorak
    Center for Vascular Biology Research and the Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Curr Opin Hematol 17:225-9. 2010
    ..The mechanisms responsible for these events have been the subject of intense investigation and, often, dispute...
  6. pmc Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma
    Harold F Dvorak
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Am J Pathol 162:1747-57. 2003
  7. ncbi request reprint Angiogenesis: update 2005
    H F Dvorak
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    J Thromb Haemost 3:1835-42. 2005
    ..Finally, it will touch on the exciting relationships that are emerging between angiogenesis and the hemostatic and nervous systems...
  8. ncbi request reprint Down syndrome candidate region 1 isoform 1 mediates angiogenesis through the calcineurin-NFAT pathway
    Liuliang Qin
    Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, 99 Brookline Avenue RN 270A, Boston, MA 02215, USA
    Mol Cancer Res 4:811-20. 2006
    ..In sum, DSCR1-1L, unlike DSCR1-4, potently activates angiogenesis and could be an attractive target for antiangiogenesis therapy...
  9. ncbi request reprint Stable expression of angiopoietin-1 and other markers by cultured pericytes: phenotypic similarities to a subpopulation of cells in maturing vessels during later stages of angiogenesis in vivo
    Christian Sundberg
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
    Lab Invest 82:387-401. 2002
    ....
  10. pmc Vascular permeability and pathological angiogenesis in caveolin-1-null mice
    Sung Hee Chang
    Center for Vascular Biology Research and the Departments of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Am J Pathol 175:1768-76. 2009
    ..Thus, caveolin-1 is not necessary for VVO structure but may have important roles in regulating VVO function in acute vascular hyperpermeability and angiogenesis...
  11. pmc Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin
    Thuy L Phung
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Cancer Cell 10:159-70. 2006
    ..Akt signaling in the tumor vascular stroma was sensitive to rapamycin, suggesting that rapamycin may affect tumor growth in part by acting as a vascular Akt inhibitor...
  12. pmc Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis
    Janice A Nagy
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
    J Exp Med 196:1497-506. 2002
    ..These findings raise the possibility that similar, abnormal lymphatics develop in other pathologies in which VEGF-A is overexpressed, e.g., malignant tumors and chronic inflammation...
  13. ncbi request reprint Ultrastructural studies define soluble macromolecular, particulate, and cellular transendothelial cell pathways in venules, lymphatic vessels, and tumor-associated microvessels in man and animals
    Dian Feng
    Department of Pathology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts 02215, USA
    Microsc Res Tech 57:289-326. 2002
    ....
  14. ncbi request reprint Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
    Harold F Dvorak
    Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Clin Oncol 20:4368-80. 2002
    ..It may also become an important target for cancer therapy...
  15. pmc VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation
    Sung Hee Chang
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Cancer Res 69:4537-44. 2009
    ....
  16. pmc The L6 protein TM4SF1 is critical for endothelial cell function and tumor angiogenesis
    Shou ching Shih
    Center for Vascular Biological Research and Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Cancer Res 69:3272-7. 2009
    ..Thus, TM4SF1 is a key regulator of EC function in vitro and of pathologic angiogenesis in vivo and is potentially an attractive target for antiangiogenesis therapy...
  17. ncbi request reprint Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin
    Ronit Satchi-Fainaro
    Children s Hospital Boston and Harvard Medical School, Vascular Biology Program, Department of Surgery, 1 Blackfan Circle, Karp Family Research Laboratories, Floor 12, Boston, Massachusetts 02115, USA
    Cancer Cell 7:251-61. 2005
    ..This activity likely contributes to TNP-470's antiangiogenic effect and suggests that caplostatin can be used in the treatment of cancer and inflammation...
  18. ncbi request reprint VEGF-A and the induction of pathological angiogenesis
    Janice A Nagy
    Department of Pathology and Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Annu Rev Pathol 2:251-75. 2007
    ..Elucidating the properties of these new vessels has led to a better understanding of angiogenesis and will hopefully lead to new approaches to antiangiogenic therapy...
  19. ncbi request reprint Ultrastructural localization of platelet endothelial cell adhesion molecule (PECAM-1, CD31) in vascular endothelium
    Dian Feng
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    J Histochem Cytochem 52:87-101. 2004
    ..We conclude that CD31 is distributed over the entire endothelial cell surface, exclusive of specialized junctions, and in VVOs, but is not equally accessible to different antibodies in all locations...
  20. pmc Orphan nuclear receptor TR3/Nur77 regulates VEGF-A-induced angiogenesis through its transcriptional activity
    Huiyan Zeng
    Department of Pathology, Gastroenterology Division, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    J Exp Med 203:719-29. 2006
    ..e., through transcriptional activity)...
  21. pmc Transcellular diapedesis is initiated by invasive podosomes
    Christopher V Carman
    The CBR Institute for Biomedical Research, Department of Pathology, Harvard Medical School, Boston, MA 02115, USA
    Immunity 26:784-97. 2007
    ..These findings provide insights into basic mechanisms for leukocyte trafficking and the functions of podosomes...
  22. ncbi request reprint VEGF-A(164/165) and PlGF: roles in angiogenesis and arteriogenesis
    Janice A Nagy
    Department of Pathology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    Trends Cardiovasc Med 13:169-75. 2003
    ....
  23. pmc Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase
    Qi Xue
    Center for Vascular Biology and the Department of Pathology at the Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Arterioscler Thromb Vasc Biol 29:1172-8. 2009
    ..We evaluated the stages of VEGF-A(164) driven angiogenesis that are inhibited by therapeutic doses of rapamycin and the potential role of S6K1 in that response...
  24. pmc Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level
    Xuefeng Zhang
    Division of Cancer Biology and Angiogenesis, Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    FASEB J 23:3368-76. 2009
    ..Moreover, 3TSR significantly decreased VEGF-stimulated VEGFR2 phosphorylation in human dermal microvascular endothelial cells in culture. Taken together, the results indicate that TSP-1 and 3TSR modulate the function of VEGFR2...
  25. pmc Heterogeneity of the tumor vasculature
    Janice A Nagy
    Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Semin Thromb Hemost 36:321-31. 2010
    ..A goal of future work is to identify therapeutic targets on tumor blood vessel endothelial cells that have lost this requirement...
  26. ncbi request reprint Permeability properties of tumor surrogate blood vessels induced by VEGF-A
    Janice A Nagy
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Lab Invest 86:767-80. 2006
    ..Extrapolating these findings to tumors predicts that only a subset of tumor vessels, MV and GMP, is hyperpermeable, and that measures of overall vessel permeability greatly underestimate the permeability of individual MV and GMP...
  27. doi request reprint Chapter 3. The adenoviral vector angiogenesis/lymphangiogenesis assay
    Janice A Nagy
    Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Methods Enzymol 444:43-64. 2008
    ..The assay can be readily extended to the study of the new blood vessels/lymphatics induced by adenoviral vectors expressing other growth factors and cytokines...

Research Grants26

  1. ADENOVIRAL VECTORS FOR DELIVERY OF ANGIOGENIC CYTOKINES
    HAROLD DVORAK; Fiscal Year: 2004
    ..Define the origins, character and fate of glomeruloid bodies. 4.Compare the angiogenic response to ischemia with that induced by VPFNEGF164 and its 120 and 188 amino acid isoforms in ischemic and non-ischemic tissues. ..
  2. PERMSELECTIVE PROPERTIES OF TUMOR AND WOUND BLOOD VESSEL
    HAROLD DVORAK; Fiscal Year: 2004
    ..abstract_text> ..
  3. Spatial and Temporal Regulation of Angiogenesis
    HAROLD DVORAK; Fiscal Year: 2006
    ..abstract_text> ..
  4. ADENOVIRAL VECTORS FOR DELIVERY OF ANGIOGENIC CYTOKINES
    HAROLD DVORAK; Fiscal Year: 2007
    ..Aim 2. Elucidate the mechanisms by which mother vessels evolve into daughter vessels. Aim 3. Generate normal blood vessels with mixtures of primary and secondary cytokines. ..
  5. Training Program in Angiogenesis & Inflammation
    HAROLD DVORAK; Fiscal Year: 2007
    ..abstract_text> ..
  6. PERMSELECTIVE PROPERTIES OF TUMOR AND WOUND BLOOD VESSEL
    HAROLD DVORAK; Fiscal Year: 1993
    ..Comparison with monoclonal antibodies. 4. Mechanism(s) by which macromolecules extravasate from the leaky blood vessels of tumors and healing wounds...